Insmed (MEX:INSM) Other Current Payables: MXN528 Mil (As of Mar. 2026)


MEX:INSM Insmed Inc MEX:INSM
68 GF Score
Price MXN3,760.00
GF Value MXN5,773.42
! 4 Warning Signs
View Full Analysis

What is Insmed Other Current Payables?

Insmed MEX:INSM 68 Other Current Payables is MXN528 Mil as of Mar. 2026. GuruFocus rates MEX:INSM with a GF Score™ of 68/100 and a GF Value™ of MXN5,773.42. The stock has 4 warning signs investors should review.

Insmed's Other Current Payables for the quarter that ended in Mar. 2026 was MXN528 Mil.

Insmed's quarterly Other Current Payables increased from Sep. 2025 (MXN263 Mil) to Dec. 2025 (MXN424 Mil) and increased from Dec. 2025 (MXN424 Mil) to Mar. 2026 (MXN528 Mil).

Insmed's annual Other Current Payables increased from Dec. 2023 (MXN153 Mil) to Dec. 2024 (MXN219 Mil) and increased from Dec. 2024 (MXN219 Mil) to Dec. 2025 (MXN424 Mil).

Insmed Other Current Payables Related Terms

Insmed Other Current Payables Historical Data

* Premium members only.

The historical data trend for Insmed's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Other Current Payables Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 136.52 133.72 153.13 219.01 424.04

Insmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 223.83 234.57 262.56 424.04 527.67
MEX:INSM
68GF Score
Insmed Inc MEX:INSM
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of MXN528 Mil mean?
Insmed (MEX:INSM) has a Other Current Payables of MXN528 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Insmed and its competitors.
Is Insmed's Other Current Payables too high?
Insmed's current Other Current Payables is MXN528 Mil. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Insmed's Other Current Payables compare to INCY and BNTX?
Insmed's Other Current Payables of MXN528 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Insmed and its competitors. Insmed's current Other Current Payables is MXN528 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Insmed (MEX:INSM) has a current Other Current Payables of MXN528 Mil. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current Other Current Payables is MXN528 Mil. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Other Current Payables is MXN528 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (MEX:INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.

Key valuation signals for MEX:INSM:

  • Other Current Payables: MXN528 Mil
  • GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score

Get the complete analysis for MEX:INSM

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,760.00
Price
MXN5,773.42
GF Value